About
Amplo Biotechnology develops AAV-based gene therapies targeting diseases of the neuromuscular junction, including Congenital Myasthenic Syndromes, muscular dystrophies, and ALS, with lead candidates AMP-101 and AMP-201 advancing toward clinical trials.
Explore Amplo Biotechnology's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.